Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes

Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the fi...

Full description

Saved in:

Bibliographic Details
Published in:	Sensors (Basel, Switzerland) Switzerland), 2020-10, Vol.20 (20), p.5920
Main Authors:	Viceconti, Marco, Hernandez Penna, Sabina, Dartee, Wilhelmus, Mazzà, Claudia, Caulfield, Brian, Becker, Clemens, Maetzler, Walter, Garcia-Aymerich, Judith, Davico, Giorgio, Rochester, Lynn
Format:	Article
Language:	eng
Subjects:	Algorithms Biomarkers Chronic obstructive pulmonary disease Clinical trials Consortia Fractures Human motion Humans inertial measurement unit Inertial sensing devices mobility performance Movement Multiple sclerosis Parkinson Disease - diagnosis Parkinson's disease Parkinsons disease Patients Qualitative research Quality of life Questionnaires regulatory science Walking Wearable technology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the first generation of these sensors was unreliable when used on slow-walking subjects. However, intense research in this area is now offering a new generation of algorithms to quantify Digital Mobility Outcomes so accurate they may be considered as biomarkers in regulatory drug trials. This perspective paper summarises the work in the Mobilise-D consortium around the regulatory qualification of the use of wearable sensors to quantify real-world mobility performance in patients affected by Parkinson's Disease. The paper describes the qualification strategy and both the technical and clinical validation plans, which have recently received highly supportive qualification advice from the European Medicines Agency. The scope is to provide detailed guidance for the preparation of similar qualification submissions to broaden the use of real-world mobility assessment in regulatory drug trials.
ISSN:	1424-8220 1424-8220